Effectiveness of In-Laboratory High-Dose Clopidogrel Loading Versus Routine Pre-Load in Patients Undergoing Percutaneous Coronary Intervention

被引:99
作者
Di Sciascio, Germano [1 ]
Patti, Giuseppe [1 ]
Pasceri, Vincenzo [2 ]
Gatto, Laura [1 ]
Colonna, Giuseppe [3 ]
Montinaro, Antonio [3 ]
机构
[1] Campus Biomed Univ Rome, Dept Cardiovasc Sci, I-00128 Rome, Italy
[2] San Filippo Neri Hosp, Intervent Cardiol Unit, Rome, Italy
[3] Vito Fazzi Hosp, Intervent Cardiol Unit, Lecce, Italy
关键词
clopidogrel; percutaneous coronary intervention; myocardial infarction; bleeding; MONITORING PLATELET INHIBITION; ACUITY ACUTE CATHETERIZATION; OF-CARE ASSAY; MYOCARDIAL-INFARCTION; RANDOMIZED-TRIAL; PROGNOSTIC-SIGNIFICANCE; ANTIPLATELET THERAPY; REDUCTION; ATORVASTATIN; DAMAGE;
D O I
10.1016/j.jacc.2010.01.067
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Objectives This study sought to evaluate safety and effectiveness of in-laboratory (in-lab) 600-mg clopidogrel loading prepercutaneous coronary intervention (PCI) versus routine 6-h pre-load. Background Clopidogrel pre-treatment significantly improves outcome in patients undergoing PCI; however, efficacy of an in-lab loading strategy before PCI after coronary angiography versus routine pre-load has not been fully characterized. Methods A total of 409 patients (39% with acute coronary syndrome) were randomized to receive a 600-mg clopidogrel loading dose 4 to 8 h before PCI (pre-load group, n = 204) or a 600-mg loading dose given in the catheterization lab after coronary angiography, but prior to PCI (in-lab group, n = 205). Primary end point was 30-day incidence of major adverse cardiac events: cardiac death, myocardial infarction (MI), or unplanned target vessel revascularization. Results There was no significant difference in primary end point between the 2 randomization arms (8.8% in-lab vs. 10.3% pre-load; p = 0.72); this was mainly driven by periprocedural MI (8.8% vs. 9.3%, p = 0.99). No increased risk of bleeding or vascular complications was observed in the pre-load arm (5.4% vs. 7.8%; p = 0.42). As determined by the VerifyNow assay (Accumetrics, San Diego, California), patients in the in-lab group showed higher platelet reactivity during PCI and 2 h after intervention versus those in the pre-load arm (p <= 0.043). Conclusions ARMYDA-5 PRELOAD (Antiplatelet therapy for Reduction of MYocardial Damage during Angioplasty) trial indicates that a strategy of 600-mg in-lab clopidogrel load pre-PCI may have similar clinical outcomes as routine 4- to 8-h pre-load. Thus, when indicated, in-lab clopidogrel administration can be a safe alternative to routine pre-treatment given before knowing patients' coronary anatomy. (J Am Coll Cardiol 2010;56:550-7) (C) 2010 by the American College of Cardiology Foundation
引用
收藏
页码:550 / 557
页数:8
相关论文
共 30 条
[1]   Myocardial infarction redefined -: A consensus Document of the Joint European Society of Cardiology/American College of Cardiology Committee for the Redefinition of Myocardial Infarction [J].
Alpert, JS ;
Antman, E ;
Apple, F ;
Armstrong, PW ;
Bassand, JP ;
de Luna, AB ;
Beller, G ;
Breithardt, G ;
Chaitman, BR ;
Clemmensen, P ;
Falk, E ;
Fishbein, MC ;
Galvani, M ;
Garson, A ;
Grines, C ;
Hamm, C ;
Jaffe, A ;
Katus, H ;
Kjekshus, J ;
Klein, W ;
Klootwijk, P ;
Lenfant, C ;
Levy, D ;
Levy, RI ;
Luepker, R ;
Marcus, F ;
Näslund, U ;
Ohman, M ;
Pahlm, O ;
Poole-Wilson, P ;
Popp, R ;
Alto, P ;
Pyörälä, K ;
Ravkilde, J ;
Rehnquist, N ;
Roberts, W ;
Roberts, R ;
Roelandt, J ;
Rydén, L ;
Sans, S ;
Simoons, ML ;
Thygesen, K ;
Tunstall-Pedoe, H ;
Underwood, R ;
Uretsky, BF ;
Van de Werf, F ;
Voipio-Pulkki, LM ;
Wagner, G ;
Wallentin, L ;
Wijns, W .
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2000, 36 (03) :959-969
[2]   ACC/AHA 2007 guide lines for the management of patients with unstable Angina/Non-ST-Elevation myocardial infraction - Executive summary [J].
Anderson, Jeffrey L. ;
Adams, Cynthia D. ;
Antman, Elliott M. ;
Bridges, Charles R. ;
Califf, Robert M. ;
Casey, Donald E., Jr. ;
Chavey, William E., II ;
Fesmire, Francis M. ;
Hochman, Judith S. ;
Levin, Thomas N. ;
Lincoff, A. Michael ;
Peterson, Eric D. ;
Theroux, Pierre ;
Wenger, Nanette Kass ;
Wright, R. Scott ;
Smith, Sidney C., Jr. ;
Jacobs, Alice K. ;
Adams, Cynthia D. ;
Riegel, Barbara .
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2007, 50 (07) :652-726
[3]   Platelet activation in patients after an acute coronary syndrome: Results from the TIMI-12 trial [J].
Ault, KA ;
Cannon, CP ;
Mitchell, J ;
McCahan, J ;
Tracy, RP ;
Novotny, WF ;
Reimann, JD ;
Braunwald, E .
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 1999, 33 (03) :634-639
[4]   Outcomes Following Pre-Operative Clopidogrel Administration in Patients With Acute Coronary Syndromes Undergoing Coronary Artery Bypass Surgery The ACUITY (Acute Catheterization and Urgent Intervention Triage strategY) Trial [J].
Ebrahimi, Ramin ;
Dyke, Cornelius ;
Mehran, Roxana ;
Manoukian, Steven V. ;
Feit, Frederick ;
Cox, David A. ;
Gersh, Bernard J. ;
Ohman, E. Magnus ;
White, Harvey D. ;
Moses, Jeffrey W. ;
Ware, James H. ;
Lincoff, A. Michael ;
Stone, Gregg W. .
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2009, 53 (21) :1965-1972
[5]   Residual platelet activity is increased in clopidogrel- and ASA-treated patients with coronary stenting for acute coronary syndromes compared with stable coronary artery disease [J].
Geisler, T. ;
Kapp, M. ;
Goehring-Frischholz, K. ;
Daub, K. ;
Doesch, C. ;
Bigalke, B. ;
Langer, H. ;
Herdeg, C. ;
Gawaz, M. .
HEART, 2008, 94 (06) :743-747
[6]   Onset and extent of platelet inhibition by clopidogrel loading in patients undergoing elective coronary stenting: The Plavix Reduction Of New Thrombus Occurrence (PRONTO) trial [J].
Gurbel, PA ;
Cummings, CC ;
Bell, CR ;
Alford, AB ;
Meister, AF ;
Serebruany, VL .
AMERICAN HEART JOURNAL, 2003, 145 (02) :239-247
[7]   Time dependence of platelet inhibition after a 600-mg loading dose of clopidogrel in a large, unselected cohort of candidates for percutaneous coronary intervention [J].
Hochholzer, W ;
Trenk, D ;
Frundi, D ;
Blanke, P ;
Fischer, B ;
Andris, K ;
Bestehorn, HP ;
Büttner, HJ ;
Neumann, FJ .
CIRCULATION, 2005, 111 (20) :2560-2564
[8]   Influence of treatment duration with a 600-mg dose of clopidogrel before percutaneous coronary revascularization [J].
Kandzari, DE ;
Berger, PB ;
Kastrati, A ;
Steinhubl, SR ;
Mehilli, J ;
Dotzer, F ;
ten Berg, JM ;
Neumann, FJ ;
Bollwein, H ;
Dirschinger, J ;
Schömig, A .
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2004, 44 (11) :2133-2136
[9]   Abciximab in patients with acute coronary syndromes undergoing percutaneous coronary intervention after clopidogrel pretreatment -: The ISAR-REACT 2 randomized trial [J].
Kastrati, A ;
Mehilli, J ;
Neumann, FJ ;
Dotzer, F ;
ten Berg, JN ;
Bollwein, H ;
Graf, I ;
Ibrahim, M ;
Pache, J ;
Seyfarth, M ;
Schühlen, H ;
Dirschinger, J ;
Berger, PB ;
Schömig, A .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2006, 295 (13) :1531-1538
[10]   Validation of a VerifyNow-P2Y12® cartridge for monitoring platelet inhibition with clopidogrel [J].
Malinin, A. ;
Pokov, A. ;
Swaim, L. ;
Kotob, M. ;
Serebruany, V. .
METHODS AND FINDINGS IN EXPERIMENTAL AND CLINICAL PHARMACOLOGY, 2006, 28 (05) :315-322